SEC Form 4 · accession 0000880771-16-000181
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lan Xie
Officer — VP Finance, China CFO
Period of report
Aug 12, 2016
Accepted (ET)
Aug 16, 2016 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2016 | M | 9,333 | $8.83 | A | 9,333 | D | |
| Common Stock | Aug 12, 2016 | S | 9,333 | $10.361 | D | 0 | D | |
| Common Stock | Aug 12, 2016 | M | 7,500 | $4.52 | A | 7,500 | D | |
| Common Stock | Aug 12, 2016 | S | 7,500 | $10.361 | D | 0 | D | |
| Common Stock | Aug 12, 2016 | M | 2,812 | $4.53 | A | 2,812 | D | |
| Common Stock | Aug 12, 2016 | S | 2,812 | $10.361 | D | 0 | D | |
| Common Stock | Aug 12, 2016 | M | 12,187 | $5.19 | A | 12,187 | D | |
| Common Stock | Aug 12, 2016 | S | 12,187 | $10.361 | D | 0 | D | |
| Common Stock | Aug 12, 2016 | M | 1,000 | $0.00 | A | 1,000 | D | |
| Common Stock | Aug 12, 2016 | S | 1,000 | $10.41 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F1,F2 | $4.52 | Aug 12, 2016 | M | 7,500 | D | — | Mar 14, 2024 | Common Stock | 7,500 | 16,667 | D |
| Non-Qualified Stock Options (right to buy)F1,F2 | $4.53 | Aug 12, 2016 | M | 2,812 | D | — | Apr 4, 2023 | Common Stock | 2,812 | 2,500 | D |
| Non-Qualified Stock Options (right to buy)F1,F2 | $5.19 | Aug 12, 2016 | M | 12,187 | D | — | Aug 1, 2022 | Common Stock | 12,187 | 0 | D |
| Non-Qualified Stock Options (right to buy)F1,F2 | $8.83 | Aug 12, 2016 | M | 9,333 | D | — | Mar 16, 2025 | Common Stock | 9,333 | 18,667 | D |
| Restricted Stock UnitF3,F4,F5 | — | Aug 12, 2016 | A | 10,000 | A | — | — | Common Stock | 10,000 | 18,000 | D |
| Restricted Stock UnitF1,F4,F6 | — | Aug 12, 2016 | M | 1,000 | D | — | — | Common Stock | 1,000 | 17,000 | D |
Explanation of responses
- F1Granted under the Issuer's 2005 Equity Incentive Plan.
- F225% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
- F3Granted under the Issuer's 2015 Equity Incentive Plan.
- F4Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F5Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
- F6Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.